SCHEMBL26490205

SCHEMBL26490205

N#CC(C#N)=C/C=C(\Cl)c1ccccc1OC(=O)c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 1/20 0.51
KMT2A Q03164 5/20 0.45
MAPT P10636 4/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
GAA P10253 2/20 0.43
HSD17B10 Q99714 4/20 0.40
LMNA P02545 3/20 0.40
ESR1 P03372 2/20 0.40
ESR2 Q92731 2/20 0.40
ALDH1A1 P00352 2/20 0.40
MEN1 O00255 1/20 0.40
JAK2 O60674 1/20 0.40
USP2 O75604 1/20 0.40
ALOX15 P16050 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
ELANE P08246 1/20 0.40
KDM4E B2RXH2 3/20 0.39
HPGD P15428 2/20 0.39
PRSS1 P07477 1/20 0.39
ACR P10323 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26091761 1.00 SLC6A3 (0.51) SLC6A3KMT2AMAPTSMN1; SMN2GAA
SCHEMBL23285672 0.85 SLC6A3 (0.54) SLC6A3KMT2AMAPTSMN1; SMN2GAA
SCHEMBL23276223 0.81 SLC6A3 (0.58) SLC6A3KMT2AMAPTSMN1; SMN2GAA
SCHEMBL23275580 0.81 SLC6A3 (0.58) SLC6A3KMT2AMAPTSMN1; SMN2GAA
SCHEMBL26092489 0.81 PARP10 (0.50) KMT2AMAPTSMN1; SMN2GAAALDH1A1
SCHEMBL23285689 0.81 PARP10 (0.50) KMT2AMAPTSMN1; SMN2GAAALDH1A1
SCHEMBL26092280 0.80 SLC6A3 (0.56) SLC6A3KMT2AMAPTSMN1; SMN2GAA
SCHEMBL23285686 0.80 SLC6A3 (0.56) SLC6A3KMT2AMAPTSMN1; SMN2GAA
SCHEMBL23275559 0.80 PARP10 (0.44) KMT2AMAPTSMN1; SMN2ALDH1A1MEN1
SCHEMBL23275555 0.78 HSD17B10 (0.47) SLC6A3KMT2AMAPTSMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230130823-A1 PROCESS FOR THE PRODUCTION OF ANTITUMOUR PHARMACEUTICAL COMPOSITIONS USING PUSH-PULL BUTADIENES, COMPOUNDS AND USES THEREOF ANHANGUERA EDUCACIONAL PARTICIPAÇÕES S/A (BR) 2023-04-27 US disclosed
US-20230130823-A1 PROCESS FOR THE PRODUCTION OF ANTITUMOUR PHARMACEUTICAL COMPOSITIONS USING PUSH-PULL BUTADIENES, COMPOUNDS AND USES THEREOF ANHANGUERA EDUCACIONAL PARTICIPAÇÕES S/A (BR) 2023-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230130823-A1 PROCESS FOR THE PRODUCTION OF ANTITUMOUR PHARMACEUTICAL COMPOSITIONS USING PUSH-PULL BUTADIENES, COMPOUNDS AND USES THEREOF BAD, BAX, PDCD4 SLC6A3 3688/4885KMT2A 4589/4885MAPT 3567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.